Online inquiry

IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4981MR)

This product GTTS-WQ4981MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA2B&ITGB3 gene. The antibody can be applied in Platelet aggregation research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000419.5; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3674; 3690
UniProt ID P08514; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4981MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14643MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ3308MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ9829MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ10454MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ7096MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ5975MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ12333MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ2933MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW